Pressure BioSciences Launches New Age in Preparation of Water-Soluble Nanoemulsions, for CBD and Other Prized Possession Oils, with Opening of UST Presentation Lab
SOUTH EASTON, Mass., Feb. 27, 2020/ PRNewswire/– Pressure BioSciences, Inc. (OTCQB: PBIO) (” PBI” or the “Company”), a leader in the development and sale of broadly allowing, pressure-based instruments, consumables, and platform technology options to the around the world biotechnology, biotherapeutics, and other industries, today announced the main opening of its brand-new Ultra Shear Technology ™ (” UST ™”) Presentation Lab (the “UST Demo Lab”). The UST Demonstration Lab lies in the Business’s South Easton, Massachusetts center.
A major purpose of the UST Demonstration Lab is to showcase the capability of the Company’s advanced UST Platform to process CBD oil into true, high quality, water-soluble nanoemulsions. A 2nd purpose is to invite potential buyers of the Company’s UST-based BaroShear Systems (preliminary release anticipated Q4 2020) to examine how their CBD and other product formulas work with the Business’s advanced UST platform.
This Company today released a new brief video showing how CBD oil from an independent maker was processed into a clear, water-soluble nanoemulsion utilizing a UST-based, first generation BaroShear system. The video reveals the CBD oil and water mix prior to and after UST processing.
Link to brand-new brief video showcasing the UST Presentation Laboratory: PBI UST CBD Video 022720
CBD and other cannabinoids are drawn out from the hemp plant in an oil kind. The water-based biology of human bodies has problem accessing and absorbing oily particles from ingested or topically applied hemp oil drops. According to Jason Ellis, President of Vegas CBD Factory, “My coworkers in the marijuana market are starting to recognize that high quality CBD items will only visit utilizing high quality, water-soluble nanoemulsions of CBD oil, such as those produced from processing CBD Oil with PBI’s UST ™ platform, which I have actually observed first-hand in their lab.”
As has been stated in the past: ‘construct it and they will come’.
Richard T. Schumacher, President and CEO of PBI commented: ” The initial reactions from producers of topical and ingestible cannabidiol products processed in our lab during the trial duration have been extremely favorable. They quickly saw how they might recognize significant expense decreases while removing the overloading of inadequately water-soluble CBD and other cannabinoids into products to attain targeted dosing levels. Our company believe our development innovation platform offers them with a new-found capability to provide safe and reliable dosing for their clients, which in turn must stimulate greater growth in the market for CBD-based products overall, and strong sales of our BaroShear product line when it is launched to the market later this year.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of ingenious, broadly enabling, pressure-based solutions for the around the world life sciences and other markets. Our items are based upon the special residential or commercial properties of both constant (i.e., fixed) and alternating (i.e., pressure cycling innovation, or PCT) hydrostatic pressure. PCT is a patented allowing technology platform that uses rotating cycles of hydrostatic pressure in between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus remains in the development of PCT-based products for biomarker and target discovery, drug style and advancement, biotherapeutics characterization and quality assurance, soil & plant biology, forensics, and counter-bioterror applications. Furthermore, significant brand-new market chances have emerged in using our pressure-based technologies in the following locations: (1) using our recently obtained, trademarked innovation from BaroFold, Inc. (the “BaroFold” innovation) to enable entry into the bio-pharma agreement services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Innovation (” UST”) platform to (i) produce stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or space temperature steady low-acid liquid foods that can not be successfully protected using existing non-thermal technologies.
Forward Looking Statements
This press release contains positive statements. These risks, unpredictabilities, and other aspects include, however are not restricted to, the threats and uncertainties talked about under the heading “Risk Elements” in the Company’s Annual Report on Form 10- K for the year ended December 31, 2018, and other reports submitted by the Business from time to time with the SEC.
For more details about PBI and this news release, please click on the following website link:
Please visit us on Facebook, LinkedIn, and Twitter.
Richard T. Schumacher, President and CEO
Kenneth F. Micciche, Director– UST Program
SOURCE Pressure BioSciences, Inc.